Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Inrig, Jula K ^a,b   Bryskin, Suzanne K ^b   Patel, Uptal D ^b,c   Arcasoy, Murat ^b   Szczech, Lynda A ^b,c  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ERYTHROPOIETIN RECEPTOR; FERRITIN; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; IRON; LEPTIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIANEMIC AGENT; CYTOKINE; IMMUNOLOGIC FACTOR;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG MEGADOSE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; MALE; PROSPECTIVE STUDY; BLOOD; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; IMMUNOLOGY; INFLAMMATION; SOLUBILITY; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATINICS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; RECEPTORS, ERYTHROPOIETIN; SOLUBILITY; TREATMENT OUTCOME;

EID: 83155185471     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-67     Document Type: Article

References (41)

1. Correction of anemia with epoetin alfa in chronic kidney disease. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, N Engl J Med 2006 355 20 2085 2098 (Pubitemid 44749317)
2. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, N Engl J Med 2006 355 20 2071 2084 (Pubitemid 44749316)
3. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA, N Engl J Med 1998 339 9 584 590 (Pubitemid 28385655)
4. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, et al. N Engl J Med 2009 361 21 2019 2032
5. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK, Kidney Int 2008 74 6 791 798
6. Epoetin requirements predict mortality in hemodialysis patients. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ, Am J Kidney Dis 2004 44 5 866 876 (Pubitemid 39445919)
7. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK, Kidney Int 2008 74 6 782 790
8. The cardiovascular effects of erythropoietin. Smith KJ, Bleyer AJ, Little WC, Sane DC, Cardiovasc Res 2003 59 3 538 548 (Pubitemid 38368670)
9. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Vaziri ND, Zhou XJ, Nephrol Dial Transplant 2009 24 4 1082 1088
10. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T, Kidney Int 1999 55 5 1899 1911 (Pubitemid 29197978)
11. Biomarkers of inflammation and progression of chronic kidney disease. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G, Kidney Int 2005 68 1 237 245 (Pubitemid 43181381)
12. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS, Am J Kidney Dis 2005 45 2 324 333 (Pubitemid 40431059)
13. Immunologic function and survival in hemodialysis patients. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH, Kidney Int 1998 54 1 236 244 (Pubitemid 28288040)
14. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK, Kidney Int 2008
15. Inflammation and resistance to erythropoiesis-stimulating agents - what do we know and what needs to be clarified? Smrzova J, Balla J, Barany P, Nephrol Dial Transplant 2005 20 Suppl 8 22iii2 7
16. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Stenvinkel P, Blood Purif 2001 19 2 143 151 (Pubitemid 32041345)
17. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJG, Balakrishnan VS, the HEMO Study Group, Nephrol Dial Transplant 2008 23 8 2619 2628
18. Isolation of a cDNA encoding a potential soluble receptor for human erythropoietin. Todokoro K, Kuramochi S, Nagasawa T, Abe T, Ikawa Y, Gene 1991 106 2 283 284
19. Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor. Nagao M, Masuda S, Abe S, Ueda M, Sasaki R, Biochem Biophys Res Commun 1992 188 2 888 897
20. Characterization of murine erythropoietin receptor genes. Kuramochi S, Ikawa Y, Todokoro K, J Mol Biol 1990 216 3 567 575 (Pubitemid 120037391)
21. Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells. Fujita M, Takahashi R, Liang P, Saya H, Ashoori F, Tachi M, Kitazawa S, Maeda S, Leukemia 1997 11 Suppl 3 444 445
22. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF, Miyazono K, Urabe A, Takaku F, J Cell Physiol 1989 140 2 323 334 (Pubitemid 19185998)
23. In vivo evidence that erythropoietin protects neurons from ischemic damage. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R, Proc Natl Acad Sci USA 1998 95 8 4635 4640 (Pubitemid 28207965)
24. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, Rosenbaum DM, Proc Natl Acad Sci USA 2002 99 16 10659 10664
25. A Novel Role for Erythropoietin During Fibrin-Induced Wound-Healing Response. Haroon ZA, Amin K, Jiang X, Arcasoy MO, Am J Pathol 2003 163 3 993 1000 (Pubitemid 37040135)
26. Enzyme-linked immunosorbent assay detects a potential soluble form of the erythropoietin receptor in human plasma. Harris KW, Winkelmann JC, Am J Hematol 1996 52 1 8 13
27. Serum form of the erythropoietin receptor identified by a sequence-specific peptide antibody. Baynes RD, Reddy GK, Shih YJ, Skikne BS, Cook JD, Blood 1993 82 7 2088 2095 (Pubitemid 23293991)
28. Detection and quantification of the soluble form of the human erythropoietin receptor (sEpoR) in the growth medium of tumor cell lines and in the plasma of blood samples. Westphal G, Braun K, Debus J, Clin Exp Med 2002 2 1 45 52 (Pubitemid 34743947)
29. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadhani R, PLoS One 2010 5 2 9246
30. Array-based ELISAs for high-throughput analysis of human cytokines. Moody MD, Van Arsdell SW, Murphy KP, Orencole SF, Burns C, Biotechniques 2001 31 1 186 190 192-184
31. Radioimmunoassay of leptin in human plasma. Ma Z, Gingerich R, Santiago J, Klein S, Smith C, Landt M, Clin Chem 1996 42 6 942 946
32. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, et al. J Am Soc Nephrol 2002 13 1 134 141 (Pubitemid 34042020)
33. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G, Nephrol Dial Transplant 2008 23 9 2879 2883
34. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Barany P, Divino Filho JC, Bergstrom J, Am J Kidney Dis 1997 29 4 565 568 (Pubitemid 27155278)
35. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD, Am J Kidney Dis 2003 42 4 761 773 (Pubitemid 37187377)
36. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC, J Am Soc Nephrol 2003 14 7 1776 1784 (Pubitemid 36750473)
37. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Macdougall IC, Cooper AC, Nephrol Dial Transplant 2002 17 Suppl 11 39 43 (Pubitemid 35277063)
38. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Kalantar-Zadeh K, Kopple JD, Am J Kidney Dis 2001 38 6 1343 1350 (Pubitemid 34193125)
39. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H, Am J Kidney Dis 1998 31 1 93 100 (Pubitemid 28116689)
40. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, et al. Kidney Int 2008 73 4 391 398 (Pubitemid 351186278)
41. Lack of relationship between soluble erythropoietin receptor levels and erythroid parameters in anemic patients. Yoshida S, Bessho M, Sakate K, Hirasawa I, Murayoshi M, Hirashima K, Blood 1996 88 8 3246 3247 (Pubitemid 26357414)